BioSpace News Archive

Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of November and December.

Nearly one in four adults in the United States suffers from chronic knee pain. New research shows the impact is widespread, causing physical, social, and mental burdens for patients on a daily basis, while also revealing that more Americans are living for years without adequate pain relief.

Novocure (NASDAQ: NVCR) today announced 25 abstracts on Tumor Treating Fields (TTFields) therapy will be featured at the Society for Neuro-Oncology (SNO) 2022 Annual Meeting from Nov. 16 to Nov. 20 in Tampa.

Alloy Therapeutics, a biotechnology ecosystem company, announced an antibody discovery collaboration spanning multiple precision immuno-oncology programs for Normunity, a biotech company that recently announced its $65 million Series A financing.

IMUNON, Inc. announced a $375,000 investment in Transomic Technologies, a private company offering a comprehensive array of CRISPR, RNAi and gene expression tools and services.

SkinCure Oncology, the world leader in providing a comprehensive model for the delivery of Image-Guided Superficial Radiotherapy, the most advanced non-surgical technology for the treatment of common skin cancers, announced the availability of the technology in North Dakota.

RenovoRx Announces Presentations at the Advanced Interventional Management Symposium (AIMsymposium) Highlighting its Innovative RenovoTAMP ® Therapy Platform for Targeted Treatment of Cancers.

RespireRx Pharmaceuticals Inc. is pleased to announce that, on November 14, 2022, the Company entered into a letter of intent with an Australia headquartered bespoke clinical research organization focused on cannabinoid and psychedelic clinical research.

Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (“Awakn”), a revenue-generating biotechnology company researching, developing, and commercializing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD)

Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing proprietary, synthetic cannabinoid derivatives, has submitted an Investigational New Drug application (“IND”) to the U.S. Food and Drug Administration for SBI-100 Ophthalmic Emulsion (“SBI-100 OE), which it is developing for the treatment of glaucoma.